The patent at issue was the University of Strathclyde's U.S.
Patent No. 9,839,706, directed to methods for inactivating
Gram-positive bacteria such as MRSA.
Claim 1 of the '706 patent recites, in relevant part:
1. A method for disinfecting air,
contact surfaces or materials by inactivating one or more
pathogenic Gram-positive bacteria in the air, on the contact
surfaces or on the materials, said method comprising exposing the
one or more pathogenic Gram-positive bacteria to visible light
without using a photosensitizer ...
The highlighted phrase was a feature at issue.
The IPR Decision
Clear-Vu challenged the patent in an Inter Partes Review (IPR)
proceeding. The PTAB found claims 1-4 obvious over two prior art
references: Ashkenazi, which reported an experiment to
photoinactivate Gram-positive bacteria using photosensitizers, and
Nitzan, which reported an experiment showing photoinactivation of
MRSA only when photosensitizers were used. The PTAB